trending Market Intelligence /marketintelligence/en/news-insights/trending/ixoAlM2A3yBSh6IyNdQVeA2 content esgSubNav
In This List

Ipsen, Blueprint Medicines collaborate to develop rare bone disease drug

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Ipsen, Blueprint Medicines collaborate to develop rare bone disease drug

France's Ipsen SA signed a licensing deal with Blueprint Medicines Corp. to develop and commercialize the latter's rare bone disease drug BLU-782.

The agreement expands Ipsen's rare diseases portfolio and supports Blueprint's goal to rapidly develop BLU-782, the companies said.

Cambridge, Mass.-based Blueprint Medicines is evaluating BLU-782 as a potential treatment of fibrodysplasia ossificans progressiva, or FOP, an ultra-rare inherited disease that causes bone to grow outside the skeleton, in tendons, muscle and soft tissue. The U.S. Food and Drug Administration already granted BLU-782 rare pediatric disease, orphan drug and fast track designations.

Under the deal, Blueprint Medicines will receive $25 million cash up front from Ipsen. Additionally, the company will receive up to $510 million in potential milestone payments, subject to achievement of specified development, regulatory and sales-based milestones for licensed products in up to two indications, including FOP.

French drugmaker Ipsen entered the agreement through its Clementia Pharmaceuticals Inc. unit, which it acquired for $1.31 billion in April.